87.17
-2.77(-3.08%)
Currency In USD
| Previous Close | 89.94 |
| Open | 90.19 |
| Day High | 90.91 |
| Day Low | 85.71 |
| 52-Week High | 95.95 |
| 52-Week Low | 30.82 |
| Volume | 1.34M |
| Average Volume | 378,846 |
| Market Cap | 3.03B |
| PE | -19.54 |
| EPS | -4.46 |
| Moving Average 50 Days | 63.66 |
| Moving Average 200 Days | 55.27 |
| Change | -2.77 |
If you invested $1000 in Disc Medicine, Inc. (IRON) since IPO date, it would be worth $846.31 as of October 20, 2025 at a share price of $87.17. Whereas If you bought $1000 worth of Disc Medicine, Inc. (IRON) shares 3 years ago, it would be worth $4,816.02 as of October 20, 2025 at a share price of $87.17.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
10 hours ago
WATERTOWN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from s
Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones
GlobeNewswire Inc.
11 hours ago
Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025, and subsequently was awarded the FDA Commissioner’s National Priority Voucher (CNPV), a program designed to sh
Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week
GlobeNewswire Inc.
Oct 17, 2025 1:00 PM GMT
WATERTOWN, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious h